Zubenko G S
Department of Psychiatry, School of Medicine, University of Pittsburgh, Pennsylvania.
Neuropsychopharmacology. 1992 Feb;6(2):77-93.
While there is considerable variation in the clinical expression of Alzheimer's disease (AD), the determinants of this clinical heterogeneity remain unclear. Platelet membrane fluidity (PMF) identifies a subgroup of patients with AD with distinct clinical features that appear to be genetically determined. Results from an integrated series of studies suggest a cellular substrate for the increase in PMF associated with this clinical subgroup, and a model for the participation of the PMF locus in the pathophysiology of AD is proposed. In addition to this approach, studies of the neuropathologic and neurochemical determinants of major depression and psychosis in the context of primary dementia are presented. The results may explain the different prognoses associated with these behavioral syndromes in patients with AD, as well as the symptoms of the syndromes themselves.
虽然阿尔茨海默病（AD）的临床表型存在相当大的差异，但其临床异质性的决定因素仍不清楚。血小板膜流动性（PMF）确定了一组具有独特临床特征的AD患者亚组，这些特征似乎由基因决定。一系列综合研究的结果表明，与该临床亚组相关的PMF增加存在细胞基础，并提出了PMF位点参与AD病理生理过程的模型。除了这种方法外，还介绍了在原发性痴呆背景下对重度抑郁和精神病的神经病理学和神经化学决定因素的研究。这些结果可能解释了AD患者中与这些行为综合征相关的不同预后，以及综合征本身的症状。
